Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER-alpha Axis.
Yazarlar (3)
Doç. Dr. Büşra Dincer Ondokuz Mayis Üniversitesi, Türkiye
Gizem Yıldıztekin Erzincan Binali Yıldırım Üniversitesi, Türkiye
Doç. Dr. İrfan ÇINAR Kastamonu Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
(SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | Chemistry and Biodiversity (Q3) | ||
| Dergi ISSN | 1612-1872 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 11-2023 |
| Cilt / Sayı / Sayfa | 20 / 10 / 2–11 | DOI | 10.1002/cbdv.202301093 |
| Makale Linki | https://pubmed.ncbi.nlm.nih.gov/37690997/ | ||
| Özet |
| This study investigates the potential of agomelatine (AGO), a synthetic melatoninergic drug, in combination with paclitaxel (PTX) for the treatment of breast cancer. The effects of AGO, PTX and melatonin (MTN) on breast cancer cell viability were investigated, focusing on the role of MT1 receptors. Cell viability and gene expression were analyzed in MCF‐7 and MDA‐MB‐231 breast cancer cell experiments. The results show that AGO has cytotoxic effects on breast cancer cells similar to MTN. Combining AGO and MTN with PTX showed synergistic effects in MCF‐7 cells. The study also reveals differences in the molecular mechanisms of breast cancer between estrogen‐positive MCF‐7 cells and estrogen‐negative MDA‐MB‐231 cells. Combination with AGO and PTX affects apoptosis‐associated proteins in both cell types. The findings suggest that AGO, combined with PTX, may be a promising adjuvant therapy for … |
| Anahtar Kelimeler |
| antitumor agents | cancer | gene expression | medicinal chemistry |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Web of Science | 1 |
| Scopus | 2 |
| Google Scholar | 2 |